top of page

For Patients
For Healthcare Professionals
- Treating Stage 4 ROS1 (for HCPs)
- ROS1 Clinical Trials
Our Research
Blog
About Us
More

Use tab to navigate through the menu items.

ROS1ders Blog

Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

All Posts
Advocacy
Biomarker Testing
Events
Patient-Driven Research
Cancer Progression
Research
Resources
Survivorship
Treatments and Trials
Fundraising
ROS1ders Stories

Search

ROS1 fusions, ROS1+ cancer, and entrectinib

ROS1 fusions, ROS1+ cancer, and entrectinib

ROS1 fusions, ROS1+ cancer, and entrectinib

Jul 25, 20232 min read

Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance

Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance

Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance

Mar 8, 20233 min read

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

Nov 9, 20223 min read

What is Targeted Therapy?

What is Targeted Therapy?

What is Targeted Therapy?

Sep 21, 20223 min read

Confused about 1st and 2nd line drugs? Here’s a guide!

Confused about 1st and 2nd line drugs? Here’s a guide!

Confused about 1st and 2nd line drugs? Here’s a guide!

Dec 29, 20192 min read

The ROS1ders Interview Dr. Ross Camidge

The ROS1ders Interview Dr. Ross Camidge

The ROS1ders Interview Dr. Ross Camidge

Janet Freeman-Daily

May 15, 20191 min read

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Janet Freeman-Daily

May 4, 20191 min read

ROS1 News From Europe

ROS1 News From Europe

ROS1 News From Europe

Bärbel Söhlke

Apr 15, 20192 min read

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Janet Freeman-Daily

Feb 18, 20191 min read

Thinking about a “drug vacation” from crizotinib? Read this first!

Thinking about a “drug vacation” from crizotinib? Read this first!

Thinking about a “drug vacation” from crizotinib? Read this first!

Janet Freeman-Daily

Jan 16, 20193 min read

Crizotinib approved for ROS1 in Australia

Crizotinib approved for ROS1 in Australia

Crizotinib approved for ROS1 in Australia

Janet Freeman-Daily

Dec 30, 20181 min read

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Janet Freeman-Daily

Dec 13, 20181 min read

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Janet Freeman-Daily

Nov 4, 20181 min read

Crizotinib may be effective again after chemo

Crizotinib may be effective again after chemo

Crizotinib may be effective again after chemo

Janet Freeman-Daily

Aug 26, 20181 min read

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Janet Freeman-Daily

Jun 14, 20181 min read

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Jan 4, 20174 min read

The ROS1ders, Inc.
1721 Eastern Avenue, Suite 19
Sacramento, CA 95864
+1 (916) 382-8544
info@theros1ders.org

A 501(c)(3) nonprofit corporation
EIN 83-4490547

Disclosures

This website is not intended to, and does not provide, medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

Connect with Our Community

Join Private Facebook Group

Email Webmaster

bottom of page